Regeneron, AstraZeneca collaborate to venture into obesity drug market

WORLD – Regeneron and AstraZeneca enter into a partnership that will focus on researching, developing and commercializing small molecule medicines targeting GPR75 for the treatment of obesity. GPR75 has emerged as a potential target for the treatment of obesity and its related co-morbidities, following findings published by Regeneron a few weeks ago in Science. The new target was identified by sequencing almost 650,000 people and identifying individuals with rare protective mutations. According to the analysis, individuals with at least one inactive copy of the GPR75 gene had lower body mass…

Read More